Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 427

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

Open access
Cochrane, Dawn R, Bernales, Sebastián, Jacobsen, Britta M, Cittelly, Diana M, Howe, Erin N, D’Amato, Nicholas C, Spoelstra, Nicole S, Edgerton, Susan M, Jean, Annie, Guerrero, Javier, Gómez, Francisco, Medicherla, Satyanarayana, Alfaro, Iván E, McCullagh, Emma, Jedlicka, Paul, Torkko, Kathleen C, Thor, Ann D, Elias, Anthony D, Protter, Andrew A, Richer, Jennifer K·2014·Breast Cancer Research

Abstract

Introduction: The androgen receptor (AR) is widely expressed in breast cancers and has been proposed as a therapeutic target in estrogen receptor alpha (ER) negative breast cancers that retain AR. However, controversy exists regarding the role of AR, particularly in ER + tumors. Enzalutamide, an AR inhibitor that impairs nuclear localization of AR, was used to elucidate the role of AR in preclinical models of ER positive and negative breast cancer. Methods: We examined nuclear AR to ER protein ratios in primary breast cancers in relation to response to endocrine therapy. The effects of AR inhibition with enzalutamide were examined in vitro and in preclinical models of ER positive and negative breast cancer that express AR. Results: In a cohort of 192 women with ER + breast cancers, a high ratio of AR:ER (≥2.0) indicated an over four fold increased risk for failure while on tamoxifen (HR = 4.43). The AR:ER ratio had an independent effect on risk for failure above ER % staining alone. AR:ER ratio is also an independent predictor of disease-free survival (HR = 4.04, 95% CI: 1.68, 9.69; p = 0.002) and disease specific survival (HR = 2.75, 95% CI: 1.11, 6.86; p = 0.03). Both enzalutamide and bicalutamide inhibited 5-alpha-dihydrotestosterone (DHT)-mediated proliferation of breast cancer lines in vitro; however, enzalutamide uniquely inhibited estradiol (E2)-mediated proliferation of ER+/AR + breast cancer cells. In MCF7 xenografts (ER+/AR+) enzalutamide inhibited E2-driven tumor growth as effectively as tamoxifen by decreasing proliferation. Enzalutamide also inhibited DHT- driven tumor growth in both ER positive (MCF7) and negative (MDA-MB-453) xenografts, but did so by increasing apoptosis. Conclusions: AR to ER ratio may influence breast cancer response to traditional endocrine therapy. Enzalutamide elicits different effects on E2-mediated breast cancer cell proliferation than bicalutamide. This preclinical study supports the initiation of clinical studies evaluating enzalutamide for treatment of AR+ tumors regardless of ER status, since it blocks both androgen- and estrogen- mediated tumor growth.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/bcr3599

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 427

Metadata

Authors
Cochrane, D. R., Bernales, S., Jacobsen, B. M., Cittelly, D. M., Howe, E. N., D’Amato, N. C., Spoelstra, N. S., Edgerton, S. M., Jean, A., Guerrero, J., Gómez, F., Medicherla, S., Alfaro, I. E., McCullagh, E., Jedlicka, P., Torkko, K. C., Thor, A. D., Elias, A. D., Protter, A. A., & Richer, J. K.
Venue
Breast Cancer Research
Published
2014-01-22
Volume
16
Issue
1
Pages
R7-R7
ISSN
  • 1465-5411 (ISSN-L)
  • 1465-542X
OpenAlex
W2107617686
Cited by
427
References
53
FWCI
23.97
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. https://app.cochat.ai/papers/10.1186/bcr3599
The paper
Cochrane, D. R., Bernales, S., Jacobsen, B. M., Cittelly, D. M., Howe, E. N., D’Amato, N. C., Spoelstra, N. S., Edgerton, S. M., Jean, A., Guerrero, J., Gómez, F., Medicherla, S., Alfaro, I. E., McCullagh, E., Jedlicka, P., Torkko, K. C., Thor, A. D., Elias, A. D., Protter, A. A., & Richer, J. K. (2014). Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Research. https://doi.org/10.1186/bcr3599

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.